Non-diabetic Overweight or Obese

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

BiocorpFrance - Issoire

2 programs

BGM0504Phase 1

Experimental: 10 mg BGM0504 10 milligramsPhase 1

BrightGeneChina - Suzhou

2 programs

BGM0504Phase 12 trials

Experimental: 10 mg BGM0504 10 milligramsPhase 11 trial

Active Trials

NCT07743983Recruiting372Est. Nov 2028

NCT07166081Completed80Est. Jul 2026

NCT06714955Completed30Est. Mar 2025

Trial Timeline

Clinical trial activity over time

2024

2025

2026

2027

2028

BrightGeneBGM0504

BrightGeneExperimental: 10 mg BGM0504 10 milligrams

Clinical Trials (3)

Total enrollment: 482 patients across 3 trials

NCT07743983 BrightGeneBGM0504

A Study of BGM0504 in Early T2DM With Obesity

Start: Sep 2026Est. completion: Nov 2028372 patients

Phase 3Recruiting

NCT07166081 BrightGeneBGM0504

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects

Start: Aug 2025Est. completion: Jul 202680 patients

Phase 1Completed

NCT06714955 BrightGeneExperimental: 10 mg BGM0504 10 milligrams

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

Start: Oct 2024Est. completion: Mar 202530 patients

Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 482 patients

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.